Rohan Rajeev

Rohan Rajeev is an intern at STAT supported by the Institute of Politics and Global Health Institute at Harvard. He is a rising senior studying neuroscience and linguistics with a secondary in classics, currently serving as an associate news editor at The Harvard Crimson. Rohan has also reported on Harvard's finances as well as religious life on campus. In his free time, he enjoys following the Premier League, logging films on Letterboxd, and playing classical piano.

Biography:  https://www.statnews.com/staff/rohan-rajeev/

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

  • Rohan Rajeev is an intern at STAT supported by the Institute of Politics and Global Health Institute at Harvard. He is a rising senior studying neuroscience and linguistics with a secondary in classics, currently serving as an associate news editor at The Harvard Crimson.

Conflicts of Interest

100%

Examples:

  • No conflicts of interest found.

Contradictions

100%

Examples:

  • No contradictions found.

Deceptions

87%

Examples:

  • Despite recommendations discouraging use of aspirin in primary prevention of cardiovascular disease among older adults, nearly a third of adults 60 years and older are still using it for this very purpose.
  • That understanding came to the forefront in 2018 as a result of three clinical trials – Ascend, Arrive, and Aspree – which elucidated the benefits and harms of aspirin beyond earlier studies of the drug conducted in the 1990s.

Recent Articles

New Study: GLP-1 Drugs Linked to Lower Risk of Obesity-Related Cancers in Type 2 Diabetes Patients

New Study: GLP-1 Drugs Linked to Lower Risk of Obesity-Related Cancers in Type 2 Diabetes Patients

Broke On: Friday, 05 July 2024 A recent JAMA Network Open study found that GLP-1 drugs, like Ozempic and Victoza, lower the risk of obesity-related cancers in Type 2 diabetes patients. The analysis of over 1.6 million patients revealed significant reductions in gallbladder (65%) and meningioma (63%) cancer risks.
One-Third of Older Adults Continue to Use Aspirin for Primary Prevention Despite Increased Bleeding Risk

One-Third of Older Adults Continue to Use Aspirin for Primary Prevention Despite Increased Bleeding Risk

Broke On: Monday, 24 June 2024 Despite updated guidelines discouraging aspirin use for primary cardiovascular disease prevention in older adults due to increased bleeding risk, one-third of adults aged 60 and above without the disease continue to consume it. Recent studies reveal that nearly 3.3 million of these individuals take preventative aspirin without medical advice. The American College of Cardiology, American Heart Association, and U.S. Preventive Services Task Force advise against aspirin use for primary prevention in adults aged 60 and above or those with increased bleeding risk.
2024 Kavli Prize Winners: Robert Langer, Paul Alivisatos, and Chad Mirkin - Revolutionizing Nanoscience in Drug Delivery, Bioimaging, and Diagnostics

2024 Kavli Prize Winners: Robert Langer, Paul Alivisatos, and Chad Mirkin - Revolutionizing Nanoscience in Drug Delivery, Bioimaging, and Diagnostics

Broke On: Wednesday, 12 June 2024 The 2024 Kavli Prize in Nanoscience is awarded to three scientists for their groundbreaking research that revolutionized nanomedicine. Robert Langer's work on controlled drug release, Paul Alivisatos' quantum dots for displays and biomarkers, and Chad Mirkin's spherical nucleic acids as diagnostic tools have significantly impacted drug delivery systems, bioimaging and diagnostics, cancer treatment using quantum dots, and diagnostic tools for diseases.